A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells

Introduction: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentat...

Full description

Bibliographic Details
Main Authors: Yasutaka Fujita, Masuhiro Nishimura, Natsuki Watanabe Komori, Tamaki Wada, Chikage Shirakawa, Taichi Takenawa, Osamu Sawamoto, Masako Doi
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Regenerative Therapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352320419301294
id doaj-98248da26c8e412f9bfdaa5afafee6a9
record_format Article
spelling doaj-98248da26c8e412f9bfdaa5afafee6a92020-11-25T02:23:35ZengElsevierRegenerative Therapy2352-32042020-06-011495102A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cellsYasutaka Fujita0Masuhiro Nishimura1Natsuki Watanabe Komori2Tamaki Wada3Chikage Shirakawa4Taichi Takenawa5Osamu Sawamoto6Masako Doi7Corresponding author. Research and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, Tokushima, 772-8601, Japan. Fax: +81 88 684 2421.; Research and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanResearch and Development Center, Otsuka Pharmaceutical Factory, Inc. Tokushima, JapanIntroduction: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentation of cells during storage and infusion. In this study, we attempted to optimize the compositions of preservation solutions, which could affect the efficacy and safety of stem cell therapy. Methods: We determined the characteristics of a preservation solution that would optimize cell viability and the percentage of cells in the supernatant using human adipose-derived mesenchymal stromal cells (hADSCs). We compared solutions that differed by electrolytes (e.g., normal saline and Ringer's solution) and the concentrations of dextran 40 and trehalose. The effects of the solutions on hADSCs were evaluated by assessing cell surface markers, colony-forming capacity, differentiation potential, and cell concentrations in the infusion line. Results: Optimized preservation solutions consisted of lactated Ringer's solution with 3% trehalose without or with 5% dextran 40 (LR-3T and LR-3T-5D, respectively). The cell viabilities after 24 h of storage at 5 °C in LR-3T and LR-3T-5D were 94.9% ± 2.4% and 97.6% ± 2.4%, respectively. The percentage of cells in the supernatant after 1 h of storage at room temperature in LR-3T-5D was 83.5% ± 7.6%. These solutions preserved the percentage of cell surface marker-positive cells, the colony-forming capacity, and the adipogenic and osteogenic differentiation ability in hADSCs for at least 24 h after preservation at 5 °C and 25 °C. Discussion: We determined the optimal composition of preservation solutions for hADSCs and confirmed the effects of these solutions on cell viability and the stability of cell characteristics in vitro. Our results suggest that LR-3T and LR-3T-5D can help maintain the quality of stem cells for therapy during preservation and infusion. However, further in vivo research is needed on the efficacy and safety of the solutions in different therapeutic cell lines before clinical use.http://www.sciencedirect.com/science/article/pii/S2352320419301294Cell preservation solutionDextran 40Human adipose-derived mesenchymal stromal cellsTrehalose
collection DOAJ
language English
format Article
sources DOAJ
author Yasutaka Fujita
Masuhiro Nishimura
Natsuki Watanabe Komori
Tamaki Wada
Chikage Shirakawa
Taichi Takenawa
Osamu Sawamoto
Masako Doi
spellingShingle Yasutaka Fujita
Masuhiro Nishimura
Natsuki Watanabe Komori
Tamaki Wada
Chikage Shirakawa
Taichi Takenawa
Osamu Sawamoto
Masako Doi
A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
Regenerative Therapy
Cell preservation solution
Dextran 40
Human adipose-derived mesenchymal stromal cells
Trehalose
author_facet Yasutaka Fujita
Masuhiro Nishimura
Natsuki Watanabe Komori
Tamaki Wada
Chikage Shirakawa
Taichi Takenawa
Osamu Sawamoto
Masako Doi
author_sort Yasutaka Fujita
title A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
title_short A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
title_full A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
title_fullStr A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
title_full_unstemmed A pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
title_sort pair of cell preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
publisher Elsevier
series Regenerative Therapy
issn 2352-3204
publishDate 2020-06-01
description Introduction: Stem cells for therapy are often suspended in a preservation solution, such as normal saline or lactated Ringer's solution, for a short time before intravenous infusion. However, these solutions are not necessarily ideal for maintaining cell viability and preventing the sedimentation of cells during storage and infusion. In this study, we attempted to optimize the compositions of preservation solutions, which could affect the efficacy and safety of stem cell therapy. Methods: We determined the characteristics of a preservation solution that would optimize cell viability and the percentage of cells in the supernatant using human adipose-derived mesenchymal stromal cells (hADSCs). We compared solutions that differed by electrolytes (e.g., normal saline and Ringer's solution) and the concentrations of dextran 40 and trehalose. The effects of the solutions on hADSCs were evaluated by assessing cell surface markers, colony-forming capacity, differentiation potential, and cell concentrations in the infusion line. Results: Optimized preservation solutions consisted of lactated Ringer's solution with 3% trehalose without or with 5% dextran 40 (LR-3T and LR-3T-5D, respectively). The cell viabilities after 24 h of storage at 5 °C in LR-3T and LR-3T-5D were 94.9% ± 2.4% and 97.6% ± 2.4%, respectively. The percentage of cells in the supernatant after 1 h of storage at room temperature in LR-3T-5D was 83.5% ± 7.6%. These solutions preserved the percentage of cell surface marker-positive cells, the colony-forming capacity, and the adipogenic and osteogenic differentiation ability in hADSCs for at least 24 h after preservation at 5 °C and 25 °C. Discussion: We determined the optimal composition of preservation solutions for hADSCs and confirmed the effects of these solutions on cell viability and the stability of cell characteristics in vitro. Our results suggest that LR-3T and LR-3T-5D can help maintain the quality of stem cells for therapy during preservation and infusion. However, further in vivo research is needed on the efficacy and safety of the solutions in different therapeutic cell lines before clinical use.
topic Cell preservation solution
Dextran 40
Human adipose-derived mesenchymal stromal cells
Trehalose
url http://www.sciencedirect.com/science/article/pii/S2352320419301294
work_keys_str_mv AT yasutakafujita apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT masuhironishimura apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT natsukiwatanabekomori apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT tamakiwada apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT chikageshirakawa apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT taichitakenawa apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT osamusawamoto apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT masakodoi apairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT yasutakafujita pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT masuhironishimura pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT natsukiwatanabekomori pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT tamakiwada pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT chikageshirakawa pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT taichitakenawa pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT osamusawamoto pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
AT masakodoi pairofcellpreservationsolutionsfortherapywithhumanadiposetissuederivedmesenchymalstromalcells
_version_ 1724858651972206592